Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LAWRENCE F EICHENFIELD

Allopathic & Osteopathic Physicians Dermatology Pediatric Dermatology

NPI
1477624138
CMS profile
339077
Location
SAN DIEGO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$428,654.73

369 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 3 of 8; records 101–150 of 369 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LAWRENCE F EICHENFIELD

NPI 1477624138 · CMS profile ID 339077

Allopathic & Osteopathic Physicians / Dermatology / Pediatric Dermatology

SAN DIEGO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 8; records 101–150 of 369 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1477624138?year=2019&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LAWRENCE F EICHENFIELD, NPI 1477624138, CMS profile ID 339077. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 8; records 101–150 of 369 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1477624138?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). LAWRENCE F EICHENFIELD, NPI 1477624138, CMS profile ID 339077. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 8; records 101–150 of 369 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1477624138?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
LAWRENCE F EICHENFIELD, NPI 1477624138, CMS profile ID 339077, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 8; records 101–150 of 369 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1477624138?year=2019&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

369 matching records · $428,654.73 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 369 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 369.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $104.9808/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659025477 CMS
PFIZER INC. $330.0008/28/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673785533 CMS
Regeneron Healthcare Solutions, Inc. $1,787.5008/28/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673373633 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $22.1808/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684575891 CMS
PFIZER INC. $2,550.0008/23/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673203665 CMS
DERMIRA, INC. $780.0008/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703882319 CMS
Eli Lilly and Company $390.4908/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657954471 CMS
Eli Lilly and Company $31.3808/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657954473 CMS
Eli Lilly and Company $11.2908/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657964779 CMS
PFIZER INC. $18.6008/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673201467 CMS
DERMIRA, INC. $3,750.0008/14/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703882321 CMS
GENZYME CORPORATION $3,861.0008/12/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694328671 CMS
PFIZER INC. $7,800.0008/12/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673211533 CMS
PFIZER INC. $7,800.0008/12/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673223265 CMS
DERMIRA, INC. $53.6208/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703880273 CMS
DERMIRA, INC. $26.6208/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703885443 CMS
Almirall LLC $10.4708/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 676653799 CMS
Regeneron Healthcare Solutions, Inc. $1,342.0008/05/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673373631 CMS
Regeneron Healthcare Solutions, Inc. $48.2707/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673373621 CMS
Regeneron Healthcare Solutions, Inc. $40.4907/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673373623 CMS
Regeneron Healthcare Solutions, Inc. $18.8507/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673373625 CMS
Regeneron Healthcare Solutions, Inc. $78.4407/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673373627 CMS
Regeneron Healthcare Solutions, Inc. $28.9207/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673373629 CMS
ALK-Abello, Inc $166.6207/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698051161 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $56.0607/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684575889 CMS
PFIZER INC. $798.3007/24/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673212393 CMS
PFIZER INC. $492.9607/24/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673214687 CMS
PFIZER INC. $130.6007/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673221643 CMS
Regeneron Healthcare Solutions, Inc. $5.4407/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673373617 CMS
Regeneron Healthcare Solutions, Inc. $118.8107/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673373619 CMS
PFIZER INC. $539.4407/23/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673217785 CMS
PFIZER INC. $160.0407/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673224239 CMS
Sun Pharmaceutical Industries Inc. $37.6207/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704584611 CMS
Almirall LLC $3,400.0007/16/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 676653795 CMS
Eli Lilly and Company $7,125.0007/02/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657954469 CMS
Regeneron Healthcare Solutions, Inc. $1,342.0007/01/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673373615 CMS
LEO Pharma AS $5.4706/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687252017 CMS
LEO Pharma AS $13,755.0006/27/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687252019 CMS
LEO Pharma AS $151.1806/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687252021 CMS
Almirall LLC $116.5306/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 676653793 CMS
PFIZER INC. $22.1606/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673213761 CMS
Regeneron Healthcare Solutions, Inc. $8,580.0006/12/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673373599 CMS
Regeneron Healthcare Solutions, Inc. $7.9506/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673373601 CMS
Regeneron Healthcare Solutions, Inc. $38.0006/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673373603 CMS
Regeneron Healthcare Solutions, Inc. $67.2606/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673373605 CMS
Regeneron Healthcare Solutions, Inc. $7.9506/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673373607 CMS
Regeneron Healthcare Solutions, Inc. $3.9706/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673373609 CMS
Regeneron Healthcare Solutions, Inc. $169.0006/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673373611 CMS
Regeneron Healthcare Solutions, Inc. $4,290.0006/12/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673373613 CMS
SANOFI-AVENTIS U.S. LLC $265.0006/12/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694056511 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $428,654.73 369
PY2020 $415,169.72 120
PY2021 $342,691.75 114
PY2022 $285,068.86 223
PY2023 $371,084.96 258
PY2024 $575,492.97 310
PY2025 $428,713.90 321

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $22,322.51 24
PY2025 Principal investigator $22,565.28 6
PY2024 Recipient $25,085.81 30
PY2024 Principal investigator $23,094.68 41
PY2023 Recipient $26,185.13 33
PY2023 Principal investigator $75,506.72 64
PY2022 Recipient $22,411.76 23
PY2022 Principal investigator $73,901.97 39
PY2021 Recipient $23,442.77 43
PY2021 Principal investigator $108,046.83 58
PY2020 Recipient $16,080.92 16
PY2020 Principal investigator $128,050.86 35
PY2019 Recipient $8,602.94 9
PY2019 Principal investigator $99,280.80 13

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

30 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Recipient Regeneron Pharmaceuticals, Inc. $416.67 12/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184117347
Recipient Regeneron Pharmaceuticals, Inc. $275.00 12/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184117349
Recipient Regeneron Pharmaceuticals, Inc. $275.00 12/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184117351
Recipient Regeneron Pharmaceuticals, Inc. $928.64 11/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184117345
Principal investigator 1 Galderma Laboratories, L.P. $1,488.00 10/29/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
A Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (aged 2 to 11 years) with Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 1234517335
Principal investigator 1 Galderma Laboratories, L.P. $4,225.00 10/29/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
A Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (aged 2 to 11 years) with Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 1234517338
Principal investigator 1 Galderma Laboratories, L.P. $2,000.00 10/29/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
A Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (aged 2 to 11 years) with Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 1234517343
Recipient GENZYME CORPORATION $500.00 10/24/2025 Covered Recipient Physician Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226089379
Principal investigator 1 Arcutis Biotherapeutics, Inc. $8,710.00 09/26/2025 Non-covered Recipient Entity
University of CA San Diego
A Phase 2, Open Label, 4-Week, Safety Study of RoflumilastCream 0.05% Administered Once Daily in Infants Aged 3Months to Less Than 2 Years with AtopicDermatitis No dispute reported 06/30/2026 1248163822
Recipient GENZYME CORPORATION $500.00 09/17/2025 Covered Recipient Physician Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226089350
Recipient PFIZER INC. $940.00 09/17/2025 Covered Recipient Physician ABROCITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228727561
Recipient GENZYME CORPORATION $500.00 06/26/2025 Covered Recipient Physician Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226089338
Recipient GENZYME CORPORATION $250.00 06/26/2025 Covered Recipient Physician Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226089361
Recipient GENZYME CORPORATION $250.00 06/25/2025 Covered Recipient Physician An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients greater than or equal to 6 to less than 18 Years of Age With Atopic Dermatitis No dispute reported 06/30/2026 1226089374
Recipient GENZYME CORPORATION $500.00 06/17/2025 Covered Recipient Physician A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of Multiple Dupilumab Dose Regimens Administered as Monotherapy for Maintaining Treatment Response in Patients With Atopic Dermatitis No dispute reported 06/30/2026 1226089331
Recipient GENZYME CORPORATION $250.00 06/17/2025 Covered Recipient Physician A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of Multiple Dupilumab Dose Regimens Administered as Monotherapy for Maintaining Treatment Response in Patients With Atopic Dermatitis No dispute reported 06/30/2026 1226089344
Recipient Regeneron Pharmaceuticals, Inc. $851.25 05/01/2025 Covered Recipient Physician AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184117343
Recipient Regeneron Pharmaceuticals, Inc. $741.07 04/01/2025 Covered Recipient Physician A PHASE 2/3 STUDY INVESTIGATING THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF DUPILUMAB IN PATIENTS AGED >=6 MONTHS TO <6 YEARS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184117339
Recipient Regeneron Pharmaceuticals, Inc. $668.22 04/01/2025 Covered Recipient Physician AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184117341
Recipient Amgen Inc. $10,124.55 03/12/2025 Covered Recipient Physician A Phase 3b, Multi Center, Open-label, Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1246637010
Recipient GENZYME CORPORATION $500.00 03/07/2025 Covered Recipient Physician An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients greater than or equal to 6 to less than 18 Years of Age With Atopic Dermatitis No dispute reported 06/30/2026 1226089355
Recipient GENZYME CORPORATION $250.00 03/07/2025 Covered Recipient Physician An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients greater than or equal to 6 to less than 18 Years of Age With Atopic Dermatitis No dispute reported 06/30/2026 1226089368
Principal investigator 1 ABBVIE INC. $1,880.95 03/06/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
M18-891 - A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 1202457779
Recipient Regeneron Pharmaceuticals, Inc. $670.68 03/01/2025 Covered Recipient Physician AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184117327
Recipient Regeneron Pharmaceuticals, Inc. $190.38 03/01/2025 Covered Recipient Physician AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184117329
Recipient Regeneron Pharmaceuticals, Inc. $1,021.50 03/01/2025 Covered Recipient Physician A PHASE 2/3 STUDY INVESTIGATING THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF DUPILUMAB IN PATIENTS AGED >=6 MONTHS TO <6 YEARS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184117331
Recipient Regeneron Pharmaceuticals, Inc. $340.91 03/01/2025 Covered Recipient Physician AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184117333
Recipient Regeneron Pharmaceuticals, Inc. $450.00 03/01/2025 Covered Recipient Physician AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184117335
Recipient Regeneron Pharmaceuticals, Inc. $928.64 03/01/2025 Covered Recipient Physician AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184117337
Principal investigator 1 Amgen Inc. $4,261.33 02/27/2025 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA AT SAN DIEGO RADY CHILDRENS HOSPITAL SAN DIEGO
A Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Re-randomization to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO) No dispute reported 06/30/2026 1246650199